Analysis of therapy effectiveness for autoimmune liver diseases in children

Kostyrko, E.V.; Shumilov, P.V.; Shigoleva, N.

doi:10.24110/0031-403x-2017-96-6-57-63

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The treatment and prevention of hepatobiliary system is an urgent task of modern pediatrics. There is a significant increase in the incidence of liver diseases of viral, toxic and medicinal etiology in children [2,4,6,9,12]. In this regard, the importance of both antiviral and systemic therapy has increased -detoxifying, metabolic, membrane-stabilizing, etc., including non-therapeutic methods, one of which is nutrition factor [5,11,13,[15][16][17].…”

Section: Introductionmentioning

confidence: 99%

In situ Testing of Biologically Active Dietary Supplement Hepar Formula in Children with Chronic Viral Hepatitis

Вековцев¹,

Плешкова²,

Avstrievskikh³

et al. 2020

Proceedings of the International Conference “Health and Wellbeing in Modern Society” (ICHW 2020)

View full text Add to dashboard Cite

A new type of biologically active dietary supplement -BADS Hepar Formula was developed. The composition of BADS was justified, which proved to have synergistic properties forming a balanced complex for the maintenance of liver metabolic processes, protection and restoration of its cells in conditions of pathological changes. A possible mechanism of participation of functional ingredients of the developed product in relation to metabolic processes in liver diseases is presented. The purpose of the study is to carry out in situ tests of Hepar Formula among children with chronic viral hepatitis. Clinical evidence of functional properties of the new type of biologically active dietary supplement is provided. The therapeutic efficacy of the developed product is studied by including BADS in the diet of 20 children aged 9 to 14 years with chronic viral hepatitis B and C in the integration phase of the infectious process. Clinical symptoms were investigated in the dynamics of dietary therapy. By the end of the treatment, good and satisfactory results were reported in 90% of the children of the main group and 80 % of the control group. The developed product contributes to the improvement of adaptation capabilities of the child's body. Side effects in the application of BADS Hepar Formula are not noted, which is essential for pediatric practice. It is possible to combine the developed product with other drugs. The results of in situ tests showed that the inclusion of BADS into the baseline therapy contributes to reparative processes in liver cells, accelerates tissue regeneration after inflammatory diseases, improves the general condition, has hepatoprotective and anti-inflammatory effects. The new kind of hepatoprotector can be used in prevention and complex treatment of chronic liver diseases. The opinion of the Expert Council of the Russian Federation was received, the developed product is included into the Federal BADS Register.

show abstract